A Phase 3 interventional study of VLA1553 and Placebo in Chikungunya Virus Infection, sponsored by Valneva Austria GmbH. Completed at 44 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Chikungunya Fever by Valneva — 2 open to participants now, 5 under way, 1 of them phase 3. Chikungunya Fever · Valneva.
Among the 11 studies in Chikungunya Fever by Valneva, this one is the only one that started in 2020, is one of 5 in phase 3, and was the 2nd registered.
88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.
Browse Chikungunya Fever studies →2 of the 11 studies in Chikungunya Fever by Valneva are open now, in 1 country. Recruiting first, the newest first:
Valneva Austria GmbH · Sites in Brazil
Ages 18+ · Women only · Healthy volunteers
Valneva Austria GmbH · Sites in Brazil
Ages 18–59 · Healthy volunteers
By country, each count listing its studies:
Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2020.
This study's enrollment of 4,128 is above the median of 263 across 57 interventional studies indexed under Chikungunya Fever.
Median enrollment 304 across the 7 interventional studies, 3,100 across the 4 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Valneva Austria GmbH, one of the names counted as Valneva. Under that name alone:
Valneva Austria GmbH is the lead sponsor of 44 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Chikungunya Fever by Valneva, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.
This was a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study and 4.128 participants aged 18 years or above were randomized in a 3:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The final dose of lyophilized VLA1553 or placebo was administered as a single intramuscular immunization. Subjects in this study were stratified into two age strata of 18 to 64 years and 65 years of age or above. The primary objective of the study was to evaluate the immunogenicity and safety of the final dose of VLA1553 28 days following the single immunization. Immunogenicity evaluations in the immunogenicity subset included the proportion of subjects with seroprotective neutralizing CHIKV antibody titers above a surrogate threshold indicative of protection. The surrogate of protection reasonably likely to predict clinical benefit has been established in non-human primate passive transfer studies using human sera from the Phase 1 study and was supported by sero-epidemiological studies. Safety data collection and immunogenicity were assessed until Month 6.
The first enrolled and randomized 501 subjects comprised the immunogenicity subset.
Inclusion Criteria:
for women of :
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
Biological: VLA1553
Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
Biological: Placebo
Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination
Seroprotection rate, based on a surrogate of protection agreed with FDA Assay used for analysis was based on µPRNT (Micro Plaque Reduction Neutralization Test). Participants at pre-selected sites were included, if they had available Day 1 and Day 29 samples and without major protocol deviations that could impact the immune response.
Time frame: on Day 29 after single vaccination
CHIKV-specific Neutralizing Antibody Titers
CHIKV-specific Neutralizing Antibody Titers on Day 8, and Day 29 Postvaccination as Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) Assay
Time frame: Until Day 180
Number of Participants With Seroprotective CHIKV Antibody Level
Seroprotection rate, based on a surrogate of protection agreed with FDA Seroprotective CHIKV Antibody Level Defined as μPRNT (Micro Plaque Reduction Neutralization Test) for Baseline Negative Subjects
Time frame: Until Day 180
Number of Participants With Seroconversion
Seroconversion was defined as CHIKV-specific neutralizing antibody titer of ≥ 20 based on µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects
Time frame: Until Day 180
Fold "Change" of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline
Fold Change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline
Time frame: until Day 180
Number of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline
Number of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline
Time frame: until Day 180
Unsolicited AEs
Number of Participants with Unsolicited Adverse Events
Time frame: Until Day 29
Solicited Injection Site AEs
Number of Participants with solicited injection site reactions
Time frame: within 10 days post-vaccination
Solicited Systemic AEs
Number of Participants with solicited systemic reactions
Time frame: within 10 days post-vaccination
Adverse Events
Number of Participants with any Adverse Events
Time frame: until Day 180
Related Adverse Events
Number of Participants with any related Adverse Events
Time frame: until Day 180
Serious Adverse Event
Number of Participants with any Serious Adverse Events
Time frame: until Day 180
Related Serious Adverse Event
Number of Participants with any Related Serious Adverse Events
Time frame: until Day 180
Adverse Event of Special Interest
Number of Participants with any Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.
Time frame: within 21 days post-vaccination
Related Adverse Event of Special Interest
Number of Participants with any Related Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.
Time frame: within 21 days post-vaccination
| Milestone | VLA1553 | Placebo |
|---|---|---|
| Started | 3082 | 1033 |
| Completed | 2724 | 920 |
| Not completed | 358 | 113 |
| Withdrew: Withdrawal by subject | 145 | 41 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 186 | 63 |
| Withdrew: Physician decision | 8 | 2 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Subject has been out of town | 1 | 0 |
| Withdrew: Subject is incarcerated | 2 | 0 |
| Withdrew: Subject is relocating | 12 | 4 |
| Withdrew: Subject in another study | 1 | 1 |
Seroprotection rate, based on a surrogate of protection agreed with FDA Assay used for analysis was based on µPRNT (Micro Plaque Reduction Neutralization Test). Participants at pre-selected sites were included, if they had available Day 1 and Day 29 samples and without major protocol deviations that could impact the immune response.
| Participants | VLA1553 18-64 Years | Placebo 18-64 Years | VLA1553 ≥65 Years | Placebo ≥65 Years |
|---|---|---|---|---|
| Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination | 204 | 0 | 59 | 0 |
CHIKV-specific Neutralizing Antibody Titers on Day 8, and Day 29 Postvaccination as Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) Assay
| Antibody Titers | VLA1553 18-64 Years | Placebo 18-64 Years | VLA1553 ≥65 Years | Placebo ≥65 Years |
|---|---|---|---|---|
| Visit 2 - Day 8 | 13.6 (12.22 to 15.23) | 10.2 (9.92 to 10.50) | 13.4 (11.05 to 16.31) | 10.0 (10.0 to 10.0) |
| Visit 3 - Day 29 | 3273.7 (2860.93 to 3746.04) | 10.1 (9.89 to 10.33) | 3688.8 (2938.94 to 4630.10) | 10.0 (10.0 to 10.0) |
| Visit 4 - Day 85 | 1068.7 (934.77 to 1221.82) | 10.0 (10.0 to 10.0) | 1140.9 (942.97 to 1380.31) | 10.7 (9.71 to 11.78) |
| Visit 5 - Day 180 | 755.1 (656.01 to 869.16) | 10.0 (10.0 to 10.0) | 742.8 (578.36 to 954.0) | 10.0 (10.0 to 10.0) |
Seroprotection rate, based on a surrogate of protection agreed with FDA Seroprotective CHIKV Antibody Level Defined as μPRNT (Micro Plaque Reduction Neutralization Test) for Baseline Negative Subjects
| Participants | VLA1553 18-64 Years | Placebo 18-64 Years | VLA1553 ≥65 Years | Placebo ≥65 Years |
|---|---|---|---|---|
| Visit 2 - Day 8 | 2 | 0 | 2 | 0 |
| Visit 4 - Day 85 | 189 | 0 | 52 | 0 |
| Visit 5 - Day 180 | 178 | 0 | 55 | 0 |
Seroconversion was defined as CHIKV-specific neutralizing antibody titer of ≥ 20 based on µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects
| Participants | VLA1553 18-64 Years | Placebo 18-64 Years | VLA1553 ≥65 Years | Placebo ≥65 Years |
|---|---|---|---|---|
| Visit 3 - Day 29 | 205 | 1 | 59 | 0 |
| Visit 5 - Day 180 | 181 | 0 | 57 | 0 |
Fold Change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline
| fold increase | VLA1553 18-64 Years | Placebo 18-64 Years | VLA1553 ≥65 Years | Placebo ≥65 Years |
|---|---|---|---|---|
| Visit 3 - Day 29 | 460.27 ± 384.052 | 1.02 ± 0.140 | 507.70 ± 412.467 | 1.00 ± 0.000 |
| Visit 5 - Day 180 | 108.81 ± 97.238 | 1.00 ± 0.000 | 102.09 ± 79.433 | 1.00 ± 0.000 |
Number of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline
| Participants | VLA1553 18-64 Years | Placebo 18-64 Years | VLA1553 ≥65 Years | Placebo ≥65 Years |
|---|---|---|---|---|
| Visit 3 - Day 29: Subjects reaching 4-fold increase | 205 | 0 | 59 | 0 |
| Visit 3 - Day 29: Subjects reaching 8-fold increase | 205 | 0 | 59 | 0 |
| Visit 3 - Day 29: Subjects reaching 16-fold increase | 204 | 0 | 59 | 0 |
| Visit 3 - Day 29: Subjects reaching 64-fold increase | 200 | 0 | 57 | 0 |
| Visit 5 - Day 180: Subjects reaching 4-fold increase | 181 | 0 | 57 | 0 |
| Visit 5 - Day 180: Subjects reaching 8-fold increase | 181 | 0 | 56 | 0 |
| Visit 5 - Day 180: Subjects reaching 16-fold increase | 177 | 0 | 55 | 0 |
| Visit 5 - Day 180: Subjects reaching 64-fold increase | 106 | 0 | 35 | 0 |
Number of Participants with Unsolicited Adverse Events
| Participants | VLA1553 | Placebo |
|---|---|---|
| Unsolicited AEs | 687 | 138 |
Number of Participants with solicited injection site reactions
| Participants | VLA1553 | Placebo |
|---|---|---|
| Any Solicited Injection Site Adverse Event | 463 | 115 |
| Tenderness | 328 | 84 |
| Pain | 191 | 38 |
| Erythema/Redness | 46 | 15 |
| Induration | 44 | 8 |
| Swelling | 21 | 8 |
Number of Participants with solicited systemic reactions
| Participants | VLA1553 | Placebo |
|---|---|---|
| Any Solicited Systemic Adverse Event | 1547 | 278 |
| Headache | 969 | 151 |
| Fatigue | 879 | 130 |
| Myalgia | 735 | 76 |
| Arthralgia | 520 | 50 |
| Fever | 414 | 8 |
| Nausea | 345 | 58 |
| Rash | 70 | 5 |
| Vomiting | 58 | 10 |
Number of Participants with any Adverse Events
| Participants | VLA1553 | Placebo |
|---|---|---|
| Mild | 1287 | 336 |
| Moderate | 532 | 112 |
| Severe | 104 | 14 |
Number of Participants with any related Adverse Events
| Participants | VLA1553 | Placebo |
|---|---|---|
| Related Adverse Events | 1575 | 322 |
Number of Participants with any Serious Adverse Events
| Participants | VLA1553 | Placebo |
|---|---|---|
| Serious Adverse Event | 46 | 8 |
Number of Participants with any Related Serious Adverse Events
| Participants | VLA1553 | Placebo |
|---|---|---|
| Related Serious Adverse Event | 2 | 0 |
Number of Participants with any Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.
| Participants | VLA1553 | Placebo |
|---|---|---|
| Adverse Event of Special Interest | 10 | 1 |
Number of Participants with any Related Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.
| Participants | VLA1553 | Placebo |
|---|---|---|
| Related Adverse Event of Special Interest | 9 | 1 |
Collected over Day 180. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VLA1553 | 2/3,082 (0.1%) | 46/3,082 (1.5%) | 1,721/3,082 (55.8%) |
| Placebo | 1/1,033 (0.1%) | 8/1,033 (0.8%) | 373/1,033 (36.1%) |
| Event | VLA1553 | Placebo |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 3/3082 | 1/1033 |
| DepressionPsychiatric disorders | 3/3082 | 0/1033 |
| COVID-19Infections and infestations | 1/3082 | 1/1033 |
| PneumoniaInfections and infestations | 2/3082 | 1/1033 |
| AnxietyPsychiatric disorders | 0/3082 | 1/1033 |
| Gastrointestinal haemorrageGastrointestinal disorders | 0/3082 | 1/1033 |
| Cerebellar haemorrhageNervous system disorders | 0/3082 | 1/1033 |
| Kidney infectionInfections and infestations | 0/3082 | 1/1033 |
| Hip fractureInjury, poisoning and procedural complications | 0/3082 | 1/1033 |
| Mental status changesPsychiatric disorders | 0/3082 | 1/1033 |
| Event | VLA1553 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 986/3082 | 160/1033 |
| FatigueGeneral disorders | 886/3082 | 137/1033 |
| MyalgiaMusculoskeletal and connective tissue disorders | 750/3082 | 82/1033 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 554/3082 | 63/1033 |
| PyrexiaGeneral disorders | 427/3082 | 13/1033 |
| Injection site painGeneral disorders | 413/3082 | 101/1033 |
| NauseaGastrointestinal disorders | 359/3082 | 63/1033 |
| RashSkin and subcutaneous tissue disorders | 82/3082 | 12/1033 |
| VomitingGastrointestinal disorders | 66/3082 | 14/1033 |
| COVID-19Infections and infestations | 59/3082 | 22/1033 |
| Age, Continuous(years) | VLA1553 | Placebo | Total |
|---|---|---|---|
| Mean | 45.1 ± 15.44 | 45.0 ± 15.59 | 45.0 ± 15.47 |
| Sex: Female, Male(Participants) | VLA1553 | Placebo | Total |
|---|---|---|---|
| Female | 1682 | 569 | 2251 |
| Male | 1400 | 464 | 1864 |
| Race/Ethnicity, Customized(Participants) | VLA1553 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 27 | 5 | 32 |
| Asian | 51 | 17 | 68 |
| Black or African American | 451 | 122 | 573 |
| Native Hawaiian or other Pacific Islander | 13 | 5 | 18 |
| White | 2456 | 853 | 3309 |
| Other | 84 | 31 | 115 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in May 2021, 8 months.
Results were first posted in Jul 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chikungunya vaccine